by enhancing quality and
yield of lentiviral vectors
by enhancing quality and
yield of lentiviral vectors
Emerging advanced therapies such as CAR-T and gene therapies have the potential to cure previously intractable conditions with a single infusion. Unfortunately, these incredible treatments remain out of the reach of many due to current vector technology limiting efficacy, quality and manufacturing viability.
Lentitek has a unique manufacturing technology that can significantly improve the production quality of the lentivirus vector used in advanced therapies and enable new applications such as in-vivo CAR-T and armoured CARs. Additionally the improvement in manufacturing quality can lead to higher yields and improved product potency. Discover how we can offer these benefits on the link below
Using a novel promoter, our proprietary method for producing lentivirus can increase the quality and yield of your vector by significantly reducing vector genome splicing and payload breakthrough expression
The Lentitek approach is easy to integrate into your current production method and does not require any changes to be made to the vector genomic sequence
Our technology can be applied to both transient transfection as well as integrated into a stable cell line production to suit a wide range of production scenarios
Floor 3, 1-4 Atholl Crescent, Edinburgh, EH3 8HA, United Kingdom
Copyright © 2025 Lentitek Ltd - All Rights Reserved.